SCHEMBL1353749

SCHEMBL1353749

Cc1cnc(NC(=O)c2cccc(N)c2)s1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.60
RAB9A P51151 12/20 0.57
NPC1 O15118 10/20 0.57
PAX8 Q06710 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.56
PKM P14618 3/20 0.56
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.54
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 4/20 0.53
HTT P42858 1/20 0.53
KDR P35968 1/20 0.51
CSNK2A2 P19784 1/20 0.51
CSNK2B P67870 1/20 0.51
CSNK2A1 P68400 1/20 0.51
CSNK2A3 Q8NEV1 1/20 0.51
SYK P43405 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8554959 0.86 RAB9A (0.70) SMN1; SMN2RAB9ANPC1PAX8MEN1
SCHEMBL7352140 0.84 SMN1; SMN2 (0.60) SMN1; SMN2RAB9ANPC1PAX8MEN1
SCHEMBL4290502 0.83 SMN1; SMN2 (0.71) SMN1; SMN2RAB9ANPC1PAX8MEN1
SCHEMBL1270133 0.83 SMN1; SMN2 (0.75) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2949867 0.82 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1PAX8MEN1
SCHEMBL17732531 0.81 SCD (0.58) SMN1; SMN2RAB9ANPC1PAX8MEN1
SCHEMBL12742436 0.80 SMN1; SMN2 (0.66) SMN1; SMN2RAB9ANPC1PAX8MEN1
SCHEMBL18175982 0.80 MEN1 (0.71) SMN1; SMN2RAB9ANPC1MEN1KMT2A
Hydrochloric Acid SCHEMBL28423065 0.79 NPC1 (0.74) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL31665552 0.78 RAB9A (0.55) SMN1; SMN2RAB9ANPC1PAX8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9579320-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 US disclosed
EP-2323993-B1 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2015-06-03 EP disclosed
US-8952027-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-02-10 US disclosed
US-20130165431-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-8349860-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-08 US disclosed
US-8318755-B2 Inhibitors of SYK and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-11-27 US disclosed
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-04-26 US disclosed
US-8063058-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-22 US disclosed
EP-2323993-A2 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS Portola Pharmaceuticals, Inc. (US) 2011-05-25 EP disclosed
CN-102066339-A 2, 6-diamino-pyrimidin-5-yl-carboxamides as SYK or JAK protein kinase inhibitors PORTOLA PHARM INC 2011-05-18 CN disclosed
US-20100048567-A1 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS INC. (US) 2010-02-25 US disclosed
WO-2009136995-A2 INHIBITORS OF SYK PROTEIN KINASE PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 SMN1; SMN2 4341/4885RAB9A 2785/4885NPC1 3576/4885
US-20130165431-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 SMN1; SMN2 4341/4885RAB9A 2785/4885NPC1 3576/4885
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 SMN1; SMN2 4341/4885RAB9A 2785/4885NPC1 3576/4885
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 SMN1; SMN2 4341/4885RAB9A 2785/4885NPC1 3576/4885
US-20100048567-A1 Inhibitors of syk and JAK protein kinases SYK, BTK, JAK1 SMN1; SMN2 4341/4885RAB9A 2785/4885NPC1 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.